tert-butyl (3,4-dimethylphenyl)carbamate | 876360-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (3,4-dimethylphenyl)carbamate
• 英文别名: tert-butyl N-(3,4-dimethylphenyl)carbamate
• CAS: 876360-88-2
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: FFVXMKPDFAFYIL-UHFFFAOYSA-N

物化性质

• 沸点：
  276.1±29.0 °C(Predicted)
• 密度：
  1.048±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl (3,4-dimethylphenyl)carbamate 在 盐酸 、 hydrazine hydrate 、 氢溴酸 、 sodium hydride 、 三乙胺 、 sodium nitrite 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 20.25h， 生成 3-(4-chlorophenyl)-N-(3,4-dimethylphenyl)-N-methyl-1-oxoisochromane-6-carboxamide
  参考文献：
  名称：

  Design, synthesis, and evaluation of compounds capable of reducing Pseudomonas aeruginosa virulence

  摘要：

  Anti-virulence approaches in the treatment of Pseudomonas aeruginosa (PA)-induced infections have shown clinical potential in multiple in vitro and in vivo studies. However, development of these compounds is limited by several factors, including the lack of molecules capable of penetrating the membrane of gram-negative organisms. Here, we report the identification of novel structurally diverse compounds that inhibit PqsR and LasR-based signaling and diminish virulence factor production and biofilm growth in two clinically relevant strains of P. aeruginosa. It is the first report where potential antivirulent agents were evaluated for inhibition of several virulence factors of PA. Finally, co-treatment with these inhibitors significantly reduced the production of virulence factors induced by the presence of subinhibitory levels of ciprofioxacin. Further, we have analyzed the drug-likeness profile of designed compounds using quantitative estimates of drug-likeness (QED) and confirmed their potential as hit molecules for further development. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2019.111800
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 3,4-二甲基苯胺 以 neat (no solvent) 为溶剂， 反应 0.17h， 以98%的产率得到tert-butyl (3,4-dimethylphenyl)carbamate
  参考文献：
  名称：

  对催化剂和无溶剂介质中的胺进行高效，快速的化学选择性BOC保护

  摘要：

  据报道，在温和的反应条件下，在无催化剂和无溶剂的介质中，绿色环保的路线几乎可以定量保护各种脂肪族和芳香族胺，氨基酸和氨基醇的BOC。产物通过1 H，13 C NMR，IR光谱和某些情况下的元素分析确认。该方案不需要任何水淬，溶剂分离和纯化步骤，例如重结晶和柱色谱法。

  DOI：

  10.1007/s11164-016-2702-9

文献信息

• Efficient and expeditious chemoselective BOC protection of amines in catalyst and solvent-free media
  作者：Balaga Viswanadham、Abdul S. Mahomed、Holger B. Friedrich、Sooboo Singh

  DOI：10.1007/s11164-016-2702-9

  日期：2017.3

  A green and eco-friendly route for the almost quantitative BOC protection of a large variety of aliphatic and aromatic amines, amino acids, and amino alcohols is reported in catalyst and solvent-free media under mild reaction conditions. The products were confirmed by 1H, 13C NMR, IR spectroscopy, and in some cases, elemental analysis. This protocol does not require any water quenches, solvent separations

  据报道，在温和的反应条件下，在无催化剂和无溶剂的介质中，绿色环保的路线几乎可以定量保护各种脂肪族和芳香族胺，氨基酸和氨基醇的BOC。产物通过1 H，13 C NMR，IR光谱和某些情况下的元素分析确认。该方案不需要任何水淬，溶剂分离和纯化步骤，例如重结晶和柱色谱法。
• Phosphoramidate Tantalum Complexes for Room-Temperature CH Functionalization: Hydroaminoalkylation Catalysis
  作者：Pierre Garcia、Ying Yin Lau、Mitchell R. Perry、Laurel L. Schafer

  DOI：10.1002/anie.201304153

  日期：2013.8.26

  A cooled reaction: Phosphoramidate–ClTaMe3 complexes promote the first example of room‐temperature hydroaminoalkylation catalysis. This reaction can be realized under solvent‐free conditions and with challenging substrates such as styrenes and dialkyl amines. When using a vinylsilane substrate, for the first time the linear regioisomer is obtained preferentially using a Group 5 metal. TBS=tert‐butyldimethylsilyl

  冷却的反应：磷酸氨基甲酸酯-ClTaMe 3络合物促进了室温加氢氨基烷基化催化作用的第一个实例。该反应可在无溶剂条件下和具有挑战性的底物（如苯乙烯和二烷基胺）下实现。当使用乙烯基硅烷底物时，首次优先使用5族金属获得线性区域异构体。TBS =叔丁基二甲基甲硅烷基，TMS =三甲基甲硅烷基。
• EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER
  申请人：Nantermet Philippe G.

  公开号：US20100197688A1

  公开（公告）日：2010-08-05

  The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.

  本发明涉及通式（I）的化合物，这些化合物是ephrin A4的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及在治疗由EphA4 RTK信号调节的疾病中使用这些化合物和组合物，例如神经系统和神经退行性疾病以及癌症。
• [EN] SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS SUBSTITUÉS DE 2, 4-DIAMINO-QUINOLÉINE POUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：GENOSCIENCE PHARMA

  公开号：WO2017191599A1

  公开（公告）日：2017-11-09

  This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non- neoplastic disorders such as rheumatoid arthritis.

  本申请披露了根据通用式（I）定义的化合物，其中所有变量如本文所述，这些化合物对各种癌细胞系表现出强烈的抑制作用。本文披露的化合物对于治疗增生性疾病非常有用，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。还披露了含有通用式（I）化合物和至少一种载体、稀释剂或赋形剂以及可选的一种或多种其他治疗活性剂的药物组合物。本申请还披露了治疗增生性疾病的方法，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎的方法。
• Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
  申请人：GENOSCIENCE PHARMA

  公开号：US10577362B2

  公开（公告）日：2020-03-03

  This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein which exhibit strong inhibition effects on various cancer cell lines. The compounds disclosed herein are useful for the treatment of proliferative diseases, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis. Also disclosed are pharmaceutical compositions containing compounds of Formula I and at least one carrier, diluent or excipient and optionally one or more additional therapeutically active agents, including anticancer agents. This application also discloses methods for treating a proliferative disease, including neoplastic diseases such as cancer and non-neoplastic disorders such as rheumatoid arthritis.

  本申请公开了符合通式 I 的化合物：其中所有变量的定义如本文所述，这些化合物对各种癌细胞系具有很强的抑制作用。本文公开的化合物可用于治疗增殖性疾病，包括肿瘤性疾病（如癌症）和非肿瘤性疾病（如类风湿性关节炎）。本申请还公开了含有式 I 化合物和至少一种载体、稀释剂或赋形剂的药物组合物，以及一种或多种额外的治疗活性剂，包括抗癌剂。本申请还公开了治疗增殖性疾病的方法，包括肿瘤性疾病如癌症和非肿瘤性疾病如类风湿性关节炎。